People in the UK attempting to lose weight are, on average, losing £369.46 each due to misinformation about weight-loss drugs, according to recent research. An estimated total of £3.3 billion is being wasted on products and treatments stemming from unsolicited, inaccurate or unsuitable advice, a study by CheqUp reveals.
Nearly two-thirds of users of GLP-1 medications reported spending money on weight-loss products or treatments influenced by advice that ultimately proved incorrect for them. Around one-third of those encountering misleading information said it originated from social media, while 18% named friends, and 8% cited casual conversations with parents at school gates as their source.
Beyond financial loss, many individuals described losing motivation and feeling uncertain about whom to trust. Lisa Tookey, CEO of CheqUp, highlighted the challenge: “People should not have to navigate prescription weight-management treatment alone. Yet, many face this daunting task amid numerous online offers, social media content, and advice exchanged among friends, family and acquaintances. Clear information, professional assessment and ongoing support are essential throughout the weight-loss journey.”
READ MORE: Christa Pike remains unconscious after failed execution attempt in Tennessee
READ MORE: Bath Rugby edge past Exeter Chiefs in thrilling West Country derby
Confusion surrounding GLP-1 treatments includes unclear guidance on counterfeit medications and doubts about identifying legitimate providers. Consequently, price often emerges as the clearest and easiest factor to compare, despite safety concerns.
More than 20% of GLP-1 users stated they chose a provider mainly based on cost. Additionally, one-fifth admitted to taking smaller doses than prescribed to extend their medication and save money, a practice that is medically inappropriate.
Furthermore, 59% had bought or considered purchasing weight-loss medication from unverified sources. Some contemplated acquiring drugs through websites without requiring consultations, purchasing off-brand medication, obtaining drugs from individuals who no longer needed them, or selecting cheaper online providers without confirming their registration.
Tookey emphasized, “When trust is lacking, price often becomes the deciding factor. However, with prescription medication, the cheapest option is not always the safest. Patients must have confidence that a qualified clinical team has evaluated their treatment, that their provider is legitimate, and that support is available for any concerns along the way. This combination of clinical oversight and personal guidance helps individuals make safer, more confident decisions.”